Burkitt lymphoma (BL) is an aggressive form of B cell lymphoma that can affect children and
adults. The study of BL led to the identification of the first recurrent chromosomal aberration …

Cisplatin is one of the most effective chemotherapy drugs for ovarian cancer, but resistance
is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in …

Cancer genome-sequencing studies have revealed a remarkably high prevalence of
mutations in genes encoding subunits of the SWI/SNF chromatin-remodelling complexes …

Epithelial ovarian cancer generally presents at an advanced stage and is the most common
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …

Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …

The first wave of genetically targeted therapies for cancer focused on drugging gene
products that are recurrently mutated in specific cancer types. However, mutational analysis …

Recent molecular genetic findings on endometriosis and normal endometrium suggest a
modified model in which circulating epithelial progenitor or stem cells intended to …

Ovarian cancer encompasses a heterogeneous group of malignancies that involve the
ovaries, fallopian tubes and the peritoneal cavity. Despite major advances made within the …

Epigenetic dysregulation is a common feature of most cancers, often occurring directly
through alteration of epigenetic machinery. Over the last several years, a new generation of …

Ovarian cancer is not a single disease and can be subdivided into at least five different
histological subtypes that have different identifiable risk factors, cells of origin, molecular …